Network meta-analysis geometry — biologics for plaque psoriasis

Network plot for a network meta-analysis with nodes sized by participants randomised to each treatment and edges weighted by the number of head-to-head trials, showing which comparisons are direct and where closed loops permit a consistency check.

Cytoscape (Network)Research & Academic Cytoscape (Network) syntax docs

Template previewCytoscape (Network)

Rendering…

Make it your own.

{
  "elements": [
    {"data":{"id":"PBO","label":"Placebo\n25 trials · 4,918 randomised","trials":25,"pts":4918}},
    {"data":{"id":"ADA","label":"Adalimumab\n11 trials · 2,140 randomised","trials":11,"pts":2140}},
    {"data":{"id":"UST","label":"Ustekinumab\n11 trials · 2,376 randomised","trials":11,"pts":2376}},
    {"data":{"id":"SEC","label":"Secukinumab\n8 trials · 1,986 randomised","trials":8,"pts":1986}},
    {"data":{"id":"IXE","label":"Ixekizumab\n6 trials · 1,742 randomised","trials":6,"pts":1742}},
    {"data":{"id":"GUS","label":"Guselkumab\n7 trials · 1,354 randomised","trials":7,"pts":1354}},
    {"data":{"id":"RIS","label":"Risankizumab\n6 trials · 1,208 randomised","trials":6,"pts":1208}},

    {"data":{"source":"PBO","target":"ADA","trials":6,"label":"6"}},
    {"data":{"source":"PBO","target":"UST","trials":4,"label":"4"}},
    {"data":{"source":"PBO","target":"SEC","trials":5,"label":"5"}},
    {"data":{"source":"PBO","target":"IXE","trials":4,"label":"4"}},
    {"data":{"source":"PBO","target":"GUS","trials":3,"label":"3"}},
    {"data":{"source":"PBO","target":"RIS","trials":3,"label":"3"}},
    {"data":{"source":"ADA","target":"UST","trials":1,"label":"1"}},
    {"data":{"source":"ADA","target":"GUS","trials":2,"label":"2"}},
    {"data":{"source":"ADA","target":"RIS","trials":2,"label":"2"}},
    {"data":{"source":"UST","target":"SEC","trials":2,"label":"2"}},
    {"data":{"source":"UST","target":"GUS","trials":2,"label":"2"}},
    {"data":{"source":"UST","target":"RIS","trials":1,"label":"1"}},
    {"data":{"source":"UST","target":"IXE","trials":1,"label":"1"}},
    {"data":{"source":"SEC","target":"IXE","trials":1,"label":"1"}}
  ],
  "layout": {"name":"circle","padding":60,"animate":false},
  "style": [
    {"selector": "node", "style": {
      "label": "data(label)",
      "width": "mapData(pts, 1200, 4920, 40, 110)",
      "height": "mapData(pts, 1200, 4920, 40, 110)",
      "background-color": "#3666ff",
      "background-opacity": 0.85,
      "border-width": 2,
      "border-color": "#1e3a8a",
      "color": "#0f172a",
      "font-size": 12,
      "text-valign": "bottom",
      "text-margin-y": 6,
      "text-wrap": "wrap",
      "text-background-color": "#ffffff",
      "text-background-opacity": 1,
      "text-background-padding": 3,
      "text-background-shape": "roundrectangle"
    }},
    {"selector": "node[id='PBO']", "style": {
      "background-color": "#64748b",
      "border-color": "#334155"
    }},
    {"selector": "edge", "style": {
      "label": "data(label)",
      "width": "mapData(trials, 1, 6, 1.5, 9)",
      "line-color": "#94a3b8",
      "curve-style": "straight",
      "font-size": 11,
      "color": "#475569",
      "text-background-color": "#ffffff",
      "text-background-opacity": 1,
      "text-background-padding": 2
    }}
  ]
}